CMEonHIV.com is dedicated to providing online CME presentations (slides with voiceover) on HIV/AIDS for healthcare professionals given by local and international experts to keep you up-to-date on the ongoing developments in the field.
Conference
"Prospective study of hyperlipidemia in ART-naīve subjects taking Combivir/abacavir (COM/ABC) vs. Combivir/nelfinavir (COM/NFV) vs. stavudine/lamivudine/nelfinavir (d4T/3TC/NFV): 48 week data" Dr. Princy N. Kumar (biography) English - 2002-04-26 - 37 minutes
Summary : Combination ARV regimens have been effective in suppressing viral loads, but are associated with long-term toxicities in some patients. The effect that PI- and non-PI-based regimens have on the development of hyperlipidemia, including lipodystrophy, is not fully known.
Gender-related differences in the development of HAART-associated
lipodystrophies are also unclear. In this talk, Dr Kumar presents 48-week data evaluating the development of hyperlipidemia as a component of the Fat Redistribution (FR) syndrome in ARV naīve subjects treated with a triple nucleoside regimen compared to two separate three-drug regimens each containing two nucleosides and a protease inhibitor. The study also takes into account gender differences.
Learning objectives : To evaluate the development of hyperlipidemia as a component of the Fat Redistribution (FR) Syndrome in antiretroviral-na?ve subjects treated with a triple nucleoside regimen compared to two separate three-drug regimens each containing two nucleosides and a protease inhibitor.
Bibliographic references : Murphy EL, Collier AC, Kalish LA, Assmann SF, Para MF, Flanigan TP, Kumar PN, Mintz L, Wallach FR, Nemo GJ; Highly active antiretroviral therapy decreases mortality and morbidity in patients with advanced HIV disease. Ann Intern Med 2001 Jul 3;135(1):17-26
USER ACKNOWLEDGES AND AGREES THAT ALL DECISIONS MADE WITH THE ASSISTANCE OR USE OF THE SOFTWARE AND/OR THE WEBSITE AND/OR BASED ON CONTENT FOUND HEREIN WILL BE EXCLUSIVELY THE RESPONSIBILITY OF THE USER.
